Catechin

Pharmacology & Research

Catechin — specifically (+)-catechin, the flavan-3-ol monomer — is one of the most studied “dietary antioxidants,” but its evidence base is a masterclass in the isolate-vs-mixture trap. Almost none of the human “catechin” literature tests this molecule. The cardiovascular and metabolic data come from green-tea catechins (a gallated mixture dominated by EGCG) or cocoa flavanols (dominated by the epimer (−)-epicatechin), and much of a plant’s flavan-3-ol content is locked into proanthocyanidins (catechin/epicatechin polymers) — a different chemical class. The one place the evidence is genuinely about isolated (+)-catechin is the withdrawn hepatitis drug cianidanol — and that story is a safety failure, not an efficacy win. Read every benefit below with the question: was the tested agent actually (+)-catechin? Almost always, no.

1. Cardiovascular & endothelial function

Genuinely strong evidence exists — for flavan-3-ol mixtures, not the monomer. A Cochrane review found flavanol-rich cocoa modestly lowers blood pressure (2 mmHg pooled) ^{1Reference 1Ried K et al. · 2017Systematic reviewEffect of cocoa on blood pressureView study →}, and a dose-response meta-analysis found cocoa flavanols improve flow-mediated dilation (+1.2%) ^{2Reference 2Sun Y et al. · 2019Meta-analysisDose-response relationship between cocoa flavanols and human endothelial function — a systematic review and meta-analysis of randomised trialsView study →}. A dietary-bioactive guideline now rates the class evidence “moderate” at 400–600 mg/day of flavan-3-ols from foods ^{4Reference 4Crowe-White KM et al. · 2022Flavan-3-ols and cardiometabolic health — first ever dietary bioactive guidelineView study →}.

Gap: the active is attributed to (−)-epicatechin and NO/endothelial signalling, not (+)-catechin — the “optimal” endothelial dose in the meta-analysis was 95 mg epicatechin versus only 25 mg (+)-catechin, the minority congener ^{2Reference 2Sun Y et al. · 2019Meta-analysisDose-response relationship between cocoa flavanols and human endothelial function — a systematic review and meta-analysis of randomised trialsView study →}. The one trial that isolated a pure monomer used (−)-epicatechin (the epimer), not (+)-catechin, and moved some biomarkers but not blood pressure or FMD ^{3Reference 3Dower JI et al. · 2015Supplementation of the pure flavonoids epicatechin and quercetin affects some biomarkers of endothelial dysfunction and inflammation in (pre)hypertensive adults (tests (−)-epicatechin, the epimer)View study →}. No RCT has ever tested isolated (+)-catechin for a cardiovascular endpoint.

2. Hepatitis (the cianidanol story)

The only human program that actually dosed isolated (+)-catechin. In the 1970s–80s the purified compound was marketed as the drug cianidanol ((+)-cyanidanol-3, “Catergen”) for viral hepatitis at gram-scale doses. The efficacy record is old and equivocal: a double-blind RCT in acute viral hepatitis (n=160, 3 g/day) reported faster normalisation of bilirubin and transaminases ^{5Reference 5Schomerus H et al. · 1984RCTSchomerus H, Wiedmann KH, Dölle W, et al. (1984). (+)-Cyanidanol-3 in the treatment of acute viral hepatitis — a randomised controlled trial. Hepatology, 4(2), 331–335. https://pubmed.ncbi.nlm.nih.gov/6368355/View study →}; a multicentre trial in chronic HBeAg-positive hepatitis found a statistically significant fall in HBeAg titre in only a minority ^{6Reference 6Suzuki H et al. · 1986RCTCianidanol therapy for HBe-antigen-positive chronic hepatitis — a multicentre, double-blind studyView study →}; a broader acute-hepatitis study showed limited, subgroup-only effects ^{7Reference 7Piazza M et al. · 1983Effect of (+)-cyanidanol-3 in acute HAV, HBV, and non-A, non-B viral hepatitisView study →}.

Gap: inconsistent efficacy, small effect sizes, and — decisively — a serious safety liability (see Toxicity) that drove the drug’s withdrawal. No regulator would carry this indication today; it survives here only as the honest record of what isolated (+)-catechin has actually been tested for ^{5,6Reference 5Schomerus H et al. · 1984RCTSchomerus H, Wiedmann KH, Dölle W, et al. (1984). (+)-Cyanidanol-3 in the treatment of acute viral hepatitis — a randomised controlled trial. Hepatology, 4(2), 331–335. https://pubmed.ncbi.nlm.nih.gov/6368355/View study →Reference 6Suzuki H et al. · 1986RCTCianidanol therapy for HBe-antigen-positive chronic hepatitis — a multicentre, double-blind studyView study →}.

3. Metabolic — weight, lipids & glucose

Green-tea catechin extracts produce small, fairly consistent effects — modest reductions in body fat ^{8,9Reference 8Nagao T et al. · 2007A green tea extract high in catechins reduces body fat and cardiovascular risks in humansView study →Reference 9Phung OJ et al. · 2010Meta-analysisEffect of green tea catechins with or without caffeine on anthropometric measures — a systematic review and meta-analysisView study →}, total and LDL cholesterol (~4–5 mg/dL) ^{10Reference 10Xu R et al. · 2020Meta-analysisEffect of green tea consumption on blood lipids — a systematic review and meta-analysis of randomised controlled trialsView study →}, and fasting glucose ^{11Reference 11Zheng XX et al. · 2013Meta-analysisEffects of green tea catechins with or without caffeine on glycaemic control in adults — a meta-analysis of randomised controlled trialsView study →} — but with small effect sizes and frequent caffeine co-intervention.

Gap: every one of these trials used an EGCG-dominated green-tea catechin mixture, not (+)-catechin, which is a trace component of tea. There is no basis to transfer the metabolic signal to the isolated monomer ^{8,10Reference 8Nagao T et al. · 2007A green tea extract high in catechins reduces body fat and cardiovascular risks in humansView study →Reference 10Xu R et al. · 2020Meta-analysisEffect of green tea consumption on blood lipids — a systematic review and meta-analysis of randomised controlled trialsView study →}.

Mechanisms

Mechanism	What it does	Relevant to	Molecule caveat
Antioxidant / radical scavenging	H-donation, metal chelation, ↓ lipid peroxidation	metabolic, general	strong in vitro; plasma (+)-catechin is nanomolar, so physiological relevance is debated
NO / endothelial signalling	↑ eNOS/NO → vasodilation, ↓ BP, ↑ FMD	cardiovascular	attributed to (−)-epicatechin, not (+)-catechin
Metabolic (lipid absorption, α-glucosidase, thermogenesis)	↓ fat/carb absorption; caffeine-linked thermogenesis	metabolic	driven by EGCG in green tea
Red-cell haptenisation	(+)-catechin + metabolites bind erythrocytes → drug-dependent/auto-antibodies	safety (haemolysis)	this one is genuinely (+)-catechin — and it is a harm

Pharmacokinetics

(+)-Catechin is absorbed as a monomer in the small intestine (largely passive diffusion), but the fraction reaching the blood intact is small and essentially none circulates as free aglycone — it is rapidly conjugated (glucuronidation, sulfation, 3′-O-methylation) in the enterocyte and liver ^{13Reference 13Di Pede G et al. · 2023Systematic reviewRevisiting the bioavailability of flavan-3-ols in humans — a systematic review and comprehensive data analysisView study →}. In the cleanest human study, pure (+)-catechin from reconstituted red wine gave a plasma peak of only ~77 nmol/L at ~1.4 h, already ~20% methylated and under 2% unconjugated within an hour ^{12Reference 12Bell JR et al. · 2000Bell JR, Donovan JL, Wong R, et al. (2000). (+)-Catechin in human plasma after ingestion of a single serving of reconstituted red wine. The American Journal of Clinical Nutrition, 71(1), 103–108. https://pubmed.ncbi.nlm.nih.gov/10617953/View study →}. These are nanomolar, transient exposures with a short half-life — the same low-plasma / rapid-conjugation pattern the broader flavan-3-ol literature reports ^{14Reference 14Manach C et al. · 2005ReviewBioavailability and bioefficacy of polyphenols in humansView study →}.

Two distinctions are load-bearing. Stereochemistry: (+)-catechin and (−)-epicatechin absorb similarly as monomers but are distinct molecules with distinct metabolite profiles, and neither is the galloylated EGCG (absorbed even more poorly) ^{15Reference 15Natsume M et al. · 2003AnimalStructures of (−)-epicatechin glucuronide identified from plasma and urine after oral ingestion of (−)-epicatechin — differences between human and ratView study →}. Polymerisation: monomers are taken up, but the proanthocyanidins are essentially not absorbed intact. The majority of any flavan-3-ol dose (~70%+) reaches the colon, where microbiota cleave the C-ring to phenyl-γ-valerolactones and phenolic acids that dominate the circulating metabolite pool and vary widely between people; mean flavan-3-ol bioavailability across human studies is only ~31% ^{13Reference 13Di Pede G et al. · 2023Systematic reviewRevisiting the bioavailability of flavan-3-ols in humans — a systematic review and comprehensive data analysisView study →}. In practical terms, oral (+)-catechin is modestly absorbed, heavily conjugated, poorly retained, and for a large fraction of any dose effectively a pro-drug for microbiome-generated valerolactones ^{13Reference 13Di Pede G et al. · 2023Systematic reviewRevisiting the bioavailability of flavan-3-ols in humans — a systematic review and comprehensive data analysisView study →}.

Clinical trials

Isolated (+)-catechin has no active modern clinical program — its only dedicated human trials were the abandoned cianidanol hepatitis studies. The large “catechin” trial literature belongs to green-tea catechin and cocoa-flavanol mixtures.

Isolated (+)-catechin	Green-tea catechins	Cocoa flavanols	Proanthocyanidins
Cianidanol (hepatitis, withdrawn)	Many RCTs (EGCG-led)	Many RCTs (epicatechin-led)	Separate class

Last checked: July 2026.

Isolate vs. Plant Studies

For catechin the isolate-vs-whole problem is unusually stark, because “catechin” names four different things. (+)-catechin (the monomer, this page) must be kept separate from (−)-epicatechin (its epimer, the main cocoa-flavanol active), from EGCG and the gallated tea catechins (the main green-tea actives), and from proanthocyanidins (the polymers most of a plant’s flavan-3-ols are locked into) ^{21Reference 21Aron PM · 2008Flavan-3-ols — nature, occurrence and biological activityView study →}. The consequence: the cardiovascular evidence is epicatechin/cocoa, the metabolic evidence is EGCG/green tea, and the polymer evidence is a different class — so a “catechin is heart-healthy” claim is an extrapolation from molecules that are not (+)-catechin. Within this database, (+)-catechin turns up as a co-occurring monomer or an antioxidant/standardisation marker (in cacao, pine, jatoba, hibiscus and others), almost always alongside epicatechin and usually without a (+)-catechin-specific assay — indeed several repo “catechin” mentions are really about epicatechin, EGCG, or condensed tannins. The one thing genuinely demonstrated for isolated (+)-catechin in humans is a harm (haemolysis, below), not a benefit.

Prevalence in Nature

(+)-Catechin is a widespread flavan-3-ol, found across the plant kingdom in cocoa, tea, pome and stone fruit (apples, peaches, apricots, cherries), grapes and red wine, berries, fava beans and Acacia catechu (the source of catechu/cutch) ^{21,24,25Reference 21Aron PM · 2008Flavan-3-ols — nature, occurrence and biological activityView study →Reference 24Arts IC et al. · 2000Catechin contents of foods commonly consumed in The NetherlandsView study →Reference 25Arts IC et al. · 2000Catechin contents of foods commonly consumed in The NetherlandsView study →}. It occurs in leaves, fruit skins and flesh, seeds and seed coats, almost always co-occurring with (−)-epicatechin, and in most plants the bulk of the flavan-3-ol mass is polymerised into proanthocyanidins — free monomeric (+)-catechin is the minor, soluble fraction. Among common foods the discrete monomer runs roughly 1–20 mg/100 g, with peaches and fava beans among the richest whole foods; red wine carries ~7 mg/100 mL (highly variable, 0–39, by variety and vinification), and — importantly — tea is not a headline (+)-catechin food despite being a headline “catechin” food, because its flavan-3-ols are overwhelmingly the gallated catechins (EGCG > ECG/EGC) ^{24,25Reference 24Arts IC et al. · 2000Catechin contents of foods commonly consumed in The NetherlandsView study →Reference 25Arts IC et al. · 2000Catechin contents of foods commonly consumed in The NetherlandsView study →}. Cocoa is genuinely flavanol-rich but epicatechin- and procyanidin-dominated, so measured dark chocolate is used as the honest cocoa-family anchor on the chart.

Biosynthetically, (+)-catechin is an end-branch of the flavonoid pathway: naringenin → dihydroflavonols → leucoanthocyanidins, from which leucoanthocyanidin reductase (LAR) makes (+)-catechin (2,3-trans) ^{22Reference 22Tanner GJ et al. · 2003Proanthocyanidin biosynthesis in plants — purification of legume leucoanthocyanidin reductase (LAR → (+)-catechin)View study →}. A parallel route runs leucoanthocyanidin → anthocyanidin → (via anthocyanidin reductase, ANR / the BANYULS gene) (−)-epicatechin (2,3-cis) ^{23Reference 23Xie DY et al. · 2003Role of anthocyanidin reductase, encoded by BANYULS, in plant flavonoid biosynthesis (ANR → (−)-epicatechin)View study →}. Both monomers are then the building blocks of the proanthocyanidins. There is essentially no non-plant dietary source — animals do not make it, and gut microbiota degrade rather than synthesise it.

Discovery & Synthesis

“Catechin” is named for catechu (also cutch or khair) — the dark, astringent extract made by boiling and evaporating the heartwood of Acacia catechu (now Senegalia catechu) and related sources, long used as a tannin, dye and astringent — from which the compound was first obtained. Catechin in turn lent its name to the catechol functional group (1,2-dihydroxybenzene). On dating: “catechu” enters English in the seventeenth century and lexicographic sources place the first use of “catechin” in the mid-1800s (attested 1853), consistent with a mid-nineteenth-century isolation from catechu — but no single first-isolator or exact year can be firmly confirmed, so treat it as approximate.

Structurally (+)-catechin is a flavan-3-ol — a flavan bearing a 3-hydroxyl (3,3′,4′,5,7-pentahydroxyflavan) — and, unusually among flavonoids, it carries no 4-oxo (ketone) and no 2,3-double bond, so its C-ring is saturated and non-planar rather than the flat, conjugated system of flavones and flavonols. With two stereocentres (C-2, C-3) it exists as four diastereomers: “catechin” is the 2,3-trans pair and “epicatechin” the 2,3-cis pair, with (+)-catechin and (−)-epicatechin the two common natural forms. Commercially it is obtained by extraction from plant material — catechu/gambier (Acacia/Uncaria), tea and other catechin-rich botanicals — followed by chromatographic purification; enantioselective total syntheses exist for research but are not the bulk route.

Patents: not yet researched (future patent-loop pass).

Toxicity & Safety

At dietary levels — tea, cocoa, apples, grapes, beans — (+)-catechin has very low toxicity and an unremarkable safety record. The concern is the concentrated, chronically dosed isolate, and here catechin carries a genuinely important, on-target cautionary tale. Marketed as the drug cianidanol (“Catergen”) in gram-scale daily doses for hepatitis, isolated (+)-catechin was withdrawn after causing acute immune (drug-induced) haemolytic anaemia — with fever, thrombocytopenia and, when haemolysis was severe and intravascular, secondary acute renal failure that could be life-threatening ^{16Reference 16Rotoli B et al. · 1985Immune-mediated acute intravascular haemolysis caused by cianidanol (Catergen)View study →}. The mechanism was worked out: cianidanol and its metabolites bind tightly to red cells, provoking both drug-dependent antibodies and, in some patients, true red-cell autoantibodies ^{17,18Reference 17Salama A · 1987Cianidanol and its metabolites bind tightly to red cells and are responsible for the production of auto- and/or drug-dependent antibodies against these cellsView study →Reference 18Pausch V · 1983Immunohaematologic examination of correlations between cyanidanol-3 therapy and haemolytic anaemiaView study →}. The reaction was episodic and resolved on stopping the drug, and it does not imply that dietary catechin causes haemolysis — but it is a documented, mechanistically understood hazard of the isolated compound at pharmacological dose ^{16,17,19Reference 16Rotoli B et al. · 1985Immune-mediated acute intravascular haemolysis caused by cianidanol (Catergen)View study →Reference 17Salama A · 1987Cianidanol and its metabolites bind tightly to red cells and are responsible for the production of auto- and/or drug-dependent antibodies against these cellsView study →Reference 19Pár A et al. · 1983Effect of (+)-cyanidanol-3 (Catergen) in chronic active hepatitisView study →}.

The best-established interaction is with iron: like other polyphenols, flavan-3-ols chelate and reduce absorption of non-heme (dietary/supplemental) iron when taken with a meal, relevant for iron-deficient people, menstruating women and pregnancy ^{20Reference 20Hurrell RF et al. · 1999Inhibition of non-haem iron absorption in man by polyphenolic-containing beveragesView study →}. CYP-enzyme and transporter effects exist in vitro but are not established as clinically meaningful for (+)-catechin at the low plasma levels diet produces, and should be read as plausibility signals, not confirmed interactions.

Dosage

There is no isolated-(+)-catechin dose in current use. The only isolated-monomer dosing precedent is the withdrawn drug cianidanol (~1.5–3 g/day for hepatitis), abandoned for the haemolysis risk above ^{5,19Reference 5Schomerus H et al. · 1984RCTSchomerus H, Wiedmann KH, Dölle W, et al. (1984). (+)-Cyanidanol-3 in the treatment of acute viral hepatitis — a randomised controlled trial. Hepatology, 4(2), 331–335. https://pubmed.ncbi.nlm.nih.gov/6368355/View study →Reference 19Pár A et al. · 1983Effect of (+)-cyanidanol-3 (Catergen) in chronic active hepatitisView study →}. Where a target is quoted, it is for flavan-3-ols as a dietary class — roughly 400–600 mg/day from foods in the dietary-bioactive guideline — which is a food-pattern recommendation (tea, cocoa, apples, berries), not a dose of the (+)-catechin monomer ^{4Reference 4Crowe-White KM et al. · 2022Flavan-3-ols and cardiometabolic health — first ever dietary bioactive guidelineView study →}.

These are descriptive, not a recommendation — no dose of isolated (+)-catechin is supported for any benefit, and the gram-scale isolate has a documented haemolysis risk. Ordinary dietary intake from foods is the sensible frame.

References